Scynexis (SCYX) Research & Development (2013 - 2026)
Scynexis' (SCYX) quarterly Research & Development came in at $3.9 million in Q2 2026, down 45.51% on a YoY basis from $7.1 million in Q2 2025, and down 68.5% quarter-over-quarter from $12.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Research & Development (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Research & Development for 14 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development fell 45.51% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $26.2 million (up 6.36% YoY), and the FY2025 full-year result was $22.3 million, down 15.62% from the prior year.
- Research & Development retreated to $3.9 million in Q2 2026 per SCYX's latest filing, from $12.4 million in the prior quarter.
- Across five years, Research & Development topped out at $12.4 million in Q1 2026 and bottomed at $3.9 million in Q2 2026.
- Historically, Research & Development has averaged $6.8 million across 5 years, with a median of $6.8 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Research & Development tumbled 59.25% in 2024, then soared 140.25% in 2026.
- Over 5 years, Research & Development stood at $7.8 million in 2022, then jumped by 34.87% to $10.6 million in 2023, then sank by 59.25% to $4.3 million in 2024, then increased by 5.35% to $4.5 million in 2025, then slipped by 14.39% to $3.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.9 million, $12.4 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 3.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.89 Mn |
| Mar 31, 2026 | 12.35 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Sep 30, 2025 | 5.45 Mn |
| Jun 30, 2025 | 7.14 Mn |
| Mar 31, 2025 | 5.14 Mn |
| Dec 31, 2024 | 4.31 Mn |
| Sep 30, 2024 | 8.07 Mn |
| Jun 30, 2024 | 6.81 Mn |
| Mar 31, 2024 | 7.21 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 6.47 Mn |
| Jun 30, 2023 | 7.04 Mn |
| Mar 31, 2023 | 6.84 Mn |
| Dec 31, 2022 | 7.85 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 7.13 Mn |
| Mar 31, 2022 | 5.74 Mn |
| Dec 31, 2021 | 7.69 Mn |
| Sep 30, 2021 | 4.40 Mn |